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Stimulated Raman scattering microscopy: an
emerging tool for drug discovery
W. J. Tipping,ab M. Lee,b A. Serrels,b V. G. Bruntonb and A. N. Hulme*a
Optical microscopy techniques have emerged as a cornerstone of biomedical research, capable of
probing the cellular functions of a vast range of substrates, whilst being minimally invasive to the cells or
tissues of interest. Incorporating biological imaging into the early stages of the drug discovery process
can provide invaluable information about drug activity within complex disease models. Spontaneous
Raman spectroscopy has been widely used as a platform for the study of cells and their components
based on chemical composition; but slow acquisition rates, poor resolution and a lack of sensitivity have
hampered further development. A new generation of stimulated Raman techniques is emerging which
allows the imaging of cells, tissues and organisms at faster acquisition speeds, and with greater
resolution and sensitivity than previously possible. This review focuses on the development of stimulated
Raman scattering (SRS), and covers the use of bioorthogonal tags to enhance sample detection, and
recent applications of both spontaneous Raman and SRS as novel imaging platforms to facilitate the
drug discovery process.
1. Introduction
The high attrition rates of candidate drugs during clinical devel-
opment remains a common feature within the pharmaceutical
industry.1–6 The industry has seen a decline in productivity, which
has been attributed to several factors including heightened
regulatory scrutiny,7 toxicity concerns8–10 and a lack of clinical
efficacy.2,10 High attrition rates may also be attributed to the
lack of dynamic readouts of drug activity in an in vivo setting;11
therefore, innovative approaches to drug screening are needed.
Incorporating imaging into complex drug screening models has
the potential to improve the robustness of preclinical studies of
drug uptake, retention and metabolism. The insight gained
from such studies could enable earlier removal of ill-fated
compounds from the development cycle, with consequential
savings in financial investment, and improve the quality of the
drug development pipeline.
The analysis of a cell, or tissue, in a native environment still
poses a significant challenge to biomedical research. Fluores-
cence microscopy has helped to address this, permitting the
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real-time imaging of fluorescently labelled molecules, includ-
ing proteins, antibodies and small molecules such as drugs or
their metabolites. However, fluorescent labels are often large
relative to the size of a small molecule, and can thus greatly
perturb the study of its intracellular properties. Intrinsic mole-
cular contrast which does not rely on the incorporation of bulky
fluorescent labels or dyes would be highly advantageous to the
analysis of small molecules in a cellular environment by
imaging; and the development of techniques based on intrinsic
molecular contrast could allow more complex imaging models
to be incorporated into the drug discovery process.
Existing label free optical technologies, such as optical
coherence tomography (OCT), do not oﬀer chemical contrast.
However, vibrational spectroscopies including infrared (IR) and
Raman spectroscopy provide potential methods for species-
specific label-free visualisation, as they generate contrast based
on chemical composition. Imaging systems based upon infra-
red spectroscopy have been reported,12 but they are limited by
the low spatial resolution imposed by the diﬀraction limit of
infrared light, and the strong IR absorption cross-section of
water and aqueous media. Raman scattering techniques oﬀer
alternative methods for cellular imaging, with the potential to
resolve some of the shortcomings associated with IR imaging.
Crucially, water has a very weak Raman scattering cross-section
and therefore molecules and cells can be studied in aqueous
environments.
Technological advances and instrumental developments
associated with Raman based microscopies have been covered
recently by Kraﬀt et al.13 Here, we provide an overview of recent
advances in stimulated Raman scattering (SRS) microscopy
with a particular focus on developments relevant for the drug
discovery process. We discuss current approaches to label-free
and near-native labelling of cellular components and small
molecules of medicinal interest for Raman imaging. We high-
light Raman tagging strategies which exploit the ‘‘silent region’’
in the Raman spectra of cells; these have allowed the develop-
ment of spectroscopically bioorthogonal tags which maximise
signal contrast. Finally, we conclude with case studies of recent
applications of Raman based microscopies, with particular
focus on SRS, and the potential of these approaches to enhance
early stage drug discovery programmes.
2. Raman microscopy
2.1 The Raman scattering process
The Raman scattering eﬀect was first observed in 1928 by
C. V. Raman, for which he received the Nobel Prize in Physics
in 1930. Raman spectroscopy has since been used to probe the
chemical nature of a vast range of substrates, by the detection
of specific chemical bonds inherent to the structure under
investigation. Raman, and its more commonly encountered
partner infrared (IR) are complementary vibrational spectro-
scopic techniques: Raman scattering probes changes in the
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polarizability of a vibrating molecule; whilst IR absorption
accompanies changes in the dipole moment of the molecule
under investigation. In Raman spectroscopy, the majority of
incident radiation does not couple with a vibrational excitation,
and the induced polarization does not change the vibrational
state the molecule started in; thus most scattered photons have
the same energy as the incident photon (Rayleigh scattering,
Fig. 1). However, when the incident radiation induces a polarisa-
tion that couples with a vibrational change in the molecule, the
photon is scattered inelastically (Raman scattering, Fig. 1). For a
molecular vibration to generate a Raman band, there must be an
associated change in the polarizability of the chemical bond,
such that there is a corresponding distortion of electron density
in the vicinity of the vibrating nuclei. Thus vibrations of multiply-
bonded or electron-rich groups, CRC, CRN and CQO for
example, produce more intense Raman bands than do vibrations
of singly-bonded or electron-deficient groups.
In spontaneous Raman spectroscopy (Fig. 2A), inelastic
scattering of the incident (pump) beam is detected as either
red-shifted (lower energy) or blue-shifted (higher energy) radiation
and is typically reported in wavenumbers (cm1). The energy
processes which occur in stimulated Raman scattering (SRS)
and coherent anti-Stokes Raman scattering (CARS) experiments
are provided in Fig. 2 for comparison, whilst further discussion
of these techniques can be found in Section 2.3.
2.2 Spontaneous Raman microscopy
Spontaneous Raman spectroscopy has seen increased usage as
an imaging platform for the analysis of cells and their contents
since pioneering work by Puppels and co-workers in 1990
on Raman spectroscopic measurements of living cells and
chromosomes.14 Raman scattering is typically a non-destructive
technique, employing relatively low energy laser irradiation, and
there is minimal interference from water in aqueous samples.
Therefore, Raman spectroscopy is suitable for live cell imaging.
Fig. 3A shows a representative cellular Raman spectrum of
pelleted SKBr3 cells, with assignments for key bands. Strikingly,
there is no contribution from cellular components in the region
1800–2800 cm1.
Acquisition of a Raman spectrum is achieved via excitation
with one fixed laser wavelength, which simultaneously induces
the inelastic scattering of all the vibrational Raman active modes
in the sample. In this way, interfacing Raman spectroscopy to
cellular imaging is easily achieved by first measuring the Raman
spectrum at each pixel, and determining the intensity of a Raman
peak of interest at each pixel to create a two-dimensional (2D)
species-specific location map. Using a chemometric technique
such as principal component analysis (PCA), it is possible to
obtain information about molecular structure and the spatial
distribution of the cellular components (Fig. 3B). Similarly, mole-
cular distribution maps of proteins (1033 cm1 & 1655 cm1) and
lipidic species (2880 cm1) can be created by plotting the signal
intensity of a peak of interest at each pixel (Fig. 3C). A three-
dimensional (3D) Raman image is constructed by scanning
the Raman probe laser through the sample point-by-point with
a laser scanning microscope. Applying dimensionality reduction
algorithms, such as clustering analysis, to the spectral data allows
the image to be segmented. In this way, Raman microscopy can
be used to generate images scaled from microscopic sub-cellular
regions of interest to macroscopic areas of tissue. Spontaneous
Raman spectroscopy has generated much interest in the medical
diagnostic field, because it has been shown that the spectral data
generated can be used to distinguish between malignant and
normal cells and tissues based on spectral characteristics. A review
of the current state of clinical applications of Raman microscopy
has been collated by Wang et al.15
To minimise late-stage drug failure there is a pressing need
to improve the early stage drug discovery processes; preclinical
modelling should aim to better mimic, and thereby predict, the
clinical response in the intended target tissue environment.16–20
This is difficult to achieve using fluorescent optical technologies,
as a fluorophore is often large relative to the small molecule
under investigation and hence perturbs its activity. Raman
spectroscopy has been used to map the interactions of small
molecules with cells;21–23 but a major challenge in extending
the methodology employed in the study of proteins and lipids
Fig. 1 Electromagnetic radiation interacting with a vibratingmolecule.When
incident radiation (o0) interacts with a chemical species, it can be elastically
scattered (Rayleigh scattering) or inelastically scattered (Raman scattering) by
an amount, om which corresponds to the energy of a molecular transition in
the molecule. In the case of Raman scattering, the scattered photon may
have a lower energy compared with the incoming photon (Stokes scattering,
o0  om), alternatively the scattered photon may have a higher energy than
the incident photon (anti-Stokes scattering, o0 + om).
Fig. 2 Schematic energy level diagrams for spontaneous Raman, stimu-
lated Raman scattering (SRS) and coherent anti-Stokes Raman scattering
(CARS) processes. (A) In spontaneous Raman, the pump beam, op, is
directed on to the sample generating a red-shifted signal os, due to
inelastic scattering. (B) During SRS two laser beams at frequencies op
and oS are incident upon the sample, such that when the frequency
diﬀerence (Do = op  oS) matches a molecular vibration in the sample
(O), stimulated emission occurs. (C) CARS microscopy is a complex
advanced Raman imaging technique, involving a four-beam mixing pro-
cess probing at the anti-Stokes frequency (oaS).
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within cellular and tissue samples, to the study of drug mole-
cules, is that these small molecules typically accumulate at
significantly lower intracellular concentrations. To date, rela-
tively high analyte concentrations have been required to enable
their detection above the cellular background signal, which
may preclude the analysis of drugs at physiologically relevant
concentrations using spontaneous Raman spectroscopy.
Furthermore, the spontaneous Raman scattering cross section
is extremely small (B1030 cm2 sr1) compared to fluorescence
(B1016 cm2 sr1), and as such, limits the speed of acquisition
of biological images by Raman spectroscopy.24,25 These limita-
tions in spontaneous Raman spectroscopy have prompted the
development of more advanced techniques.
2.3 Stimulated Raman scattering microscopy
Coherent Raman scattering microscopy techniques, based on
either coherent anti-Stokes Raman scattering (CARS) or stimu-
lated Raman scattering (SRS), have been developed to overcome
the low signal levels associated with spontaneous Raman
imaging, and hence enhance real-time vibrational imaging of
living cells and organisms. SRS was first reported in 1962,26
although it is only recently that the potential of SRS as an
alternative Raman imaging platform has been realised. Table 1
highlights some of the key advantages of SRS over its more
widely-known counterpart CARS.
SRS signals are generated by the co-alignment of two incident
beams (the pump and Stokes beams). By tuning the frequency
diﬀerence (Do = op os) between the beams to match a molecular
vibration (O), stimulated excitation of the Raman active molecular
vibration occurs (see Fig. 2B). This process causes an intensity
loss in the pump beam (stimulated Raman loss, SRL) and an
intensity gain in the Stokes beam (stimulated Raman gain,
SRG). By modulating one of the beams (typically, the Stokes
beam) using either an electro-optic modulator (EOM), or an
acousto-optic modulator (AOM), the change in pump beam can
be measured using radio-frequency lock-in detection providing
a contrast to generate an image (Fig. 4).27
Conversely, when Do does not match a molecular vibration
within the sample, SRL and SRG cannot occur. As a result, there
is no associated non-resonant background, rendering image
analysis much simpler than in CARS imaging. In comparison
to SRS, during the CARS process, no energy is transferred to
the sample, rather, the energy diﬀerence between the pump-
and Stokes-photons is emitted at the anti-Stokes frequency
(see Fig. 2B).28 Consequently, CARS processes can occur when
there are no resonant molecules in the field of view, giving rise
to non-resonant background eﬀects. This background can limit
the detection sensitivity and also result in a distortion of the
CARS spectra from the spontaneous Raman spectrum.28 However,
CARS processes are typically more intense than SRS signals, and
Fig. 3 Label-free imaging of SKBr3 cells by Raman microscopy.
(A) Spontaneous Raman spectrum of SKBr3 cell pellet measured using
785 nm excitation. Key bands are indicted, with wavenumbers measured in
cm1. (B) Spontaneous Raman image of two fixed SKBr3 cells, in the region
2100–3100 cm1, with principal component analysis to identify different
regions of the cell. Blue: principal component 1, yellow: principal compo-
nent 2, red: principal component 3, black: principal component 4. Scale
bar 10 mm. (C) Molecular distribution maps of fixed SKBr3 cells by Raman
microscopy, (i) extracted image at 1033 cm1 (C–H in-plane of phenylalanine);
(ii) extracted image at 1657 cm1 (CQO, amide-I); (iii) extracted image
at 2880 cm1 (CH2, lipid); and (iv) extracted image at 2939 cm
1 (CH3).
Scale bars 5 mm.
Table 1 Comparison between CARS and SRS imaging techniques
CARS SRS
CARS signal generated at new
optical frequency (oaS)
Intensity gain (SRG) and intensity
loss (SRL) in incident beams
Non-resonant background
artefacts
No non-resonant background present
Non-linear concentration
dependence
Linear concentration dependence
Spectral distortion can occur Spectra match spontaneous
Raman spectrum
Fig. 4 Output spectrum associated with SRS process. The Stokes beam
experiences an intensity gain resulting from the stimulated excitation of a
Raman active band within the target molecule (SRG). Conversely, the
pump beam experiences an intensity loss during this process (SRL).
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CARS microscopy has been successfully applied to the direct
visualisation of cells and tumour micro-environments.29,30
Ploetz et al. described the first femtosecond stimulated
Raman scattering microscope in 2007.31 Fig. 5 provides a
schematic overview of a SRS microscope, central to which is
the synchronised pairing of the pump and Stokes beams. These
beams are spatially overlapped via a dichroic mirror and
co-lineated into a beam-scanning microscope. An objective lens
focuses the beams onto a common focal spot within the target
sample which generates a stimulated Raman process at its
focus. A high numerical aperture condenser collects the trans-
mitted beams, with a filter blocking the Stokes beam and
subsequent detection of the pump beam is achieved via a
photo-diode. A lock-in amplifier is used to extract the SRL signal
from the laser intensity, providing a Raman intensity value at
each pixel (Fig. 6).
Three-dimensional imaging is achieved by raster scanning
the laser focus across the sample and moving the focus depth
into the sample. Separating the frequency of the two laser pulses
by the vibrational frequency of a molecular transition (O) in the
target sample, results in only a single specific vibrational level in
the sample being probed.
SRS systems with picosecond pulses are ideal for probing
single Raman vibrations as the Raman line width is typically
around 10 cm1, comparable to the spectral width of a several
picosecond pulse.32 In the presence of several overlapping
Raman bands from diﬀerent species, more spectral informa-
tion may be required to aid separation and identification of
the component vibrations. Hyperspectral stimulated Raman
scattering (hsSRS) with picosecond sources can be achieved
by tuning the pump or Stokes laser through the desired
wavelength range33,34 although this can be a time consuming
process often taking several minutes and may be susceptible to
optical power drift and wavelength drift. Faster methods have
been developed using femtosecond lasers, where spectrally
broad pulses can be modulated using pulse shapers, spectral
focusing, or spectral filtering to achieve rapid scanning of
diﬀering frequencies.35–37
To further suppress background signals, spectrally modu-
lated SRS has been developed by Zhang et al.38 Two spectrally
narrow bands are cut from a broadband femtosecond pulse,
probing on- and oﬀ-resonance pulses, and switched at high
frequencies. Intensity modulation of a single beam generates
other heterodyne contrast such as photothermal lensing, cross-
phase modulation and transient absorption. By spectrally
modulating the beam only the Raman eﬀect is detected, which
can be vital in pigmented cells.39 Spectrally tailoring the
excitation to modulate between a target species and interfering
species can also be used, when correctly weighted, to cancel out
the interfering species Raman contribution.40
For thick and opaque samples, such as tissue, where up to
45% of the incident photons may be back scattered, epi-
detection of the SRS signals can be required.41 Back scattered
light, which has scrambled phase and polarisation, can be
collected by the objective lens and separated from the incident
light using a polarising beam splitter.42,43 However, a more
eﬃcient method has been demonstrated by Ito et al. where a
large area photodiode is placed between the objective lens
and the sample to collect the majority of back scattered photons
which fall outside of the objective lens.44 An alternative approach
to improving image resolution in SRS microscopy has recently
been reported which combines stimulated Raman scattering
microscopy with tip enhanced Raman spectroscopy (TERS)
imaging.45
Fig. 5 A schematic representation of a SRS microscope. A pump beam
and an intensity-modulated Stokes beam are both temporally and spatially
synchronized before being focused onto cells. When the energy diﬀerence
between the pump photons and the Stokes photons matches the mole-
cular vibration (O) of a bond, those particular bonds are eﬃciently driven
from their vibrational ground state to their vibrational excited state, passing
through a virtual state. For each excited bond, a photon in the pump beam
is annihilated (Raman loss) and a photon in the Stokes beam is created
(Raman gain). These intensity changes in the pump beam are extracted
using a lock-in amplifier and can provide a quantitative map of the targeted
vibrating chemical bonds.
Fig. 6 Label free microscopy of squamous cell carcinoma cells by sti-
mulated Raman scattering microscopy. (A) Stimulated Raman scattering
image of fixed SCC cells, (i) acquired at 2953 cm1 (CH3); (ii) acquired at
2850 cm1 (CH2, lipid); (iii) acquired at 1655 cm
1 (CQO, amide-1); and
(iv) acquired at 1700 cm1 (cellular silent region). Scale bars 5 mm.
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These developments mean that SRS images can now be
generated across a range of cell and tissue environments, giving
high resolution data that is appropriate for use in preclinical
applications (see Section 4). Limitations arising from the Raman-
based detection of the drug molecule itself in the intracellular
environment have been addressed using a number of strategies
as outlined in Section 3.
3. Enhanced detection in SRS
Strategies aimed at enhancing the visualisation and quantitation
of biomolecules by Raman microscopy have focused not only on
the use of more powerful Raman scattering techniques such as
SRS, but also on the introduction of small Raman-active tags to
enhance detectability. These tagging strategies frequently exploit
the cellular silent region of the Raman spectrum (i.e. they are
spectroscopically bioorthogonal), where there is minimal back-
ground interference from intrinsic cellular components.46 Two
main strategies are employed in the design of Raman-active tags:
the first is the use of bioorthogonal Raman-active groups which
are either inherent to the molecule under investigation, or are
selectively introduced for imaging purposes. The second is the
use of isotopologues (i.e. compounds which diﬀer from the
parent structure only by an isotopic substitution), which again
can be selected to give Raman-active bands in the cellular silent
region. Table 2 summarises some of the key Raman-active tags
that have been used for cell-based imaging.
3.1 Bioorthogonal Raman tags for imaging
Cell imaging using inherent Raman bands, e.g. CH2 bands
(indicative of lipids and fatty acids) and the amide-I CQO band
(indicative of proteins), has enabled the intracellular mapping
of these species. However, imaging the uptake of drugs and
drug carriers presents a significant challenge using conven-
tional Raman microscopy, since these frequently accumulate at
much lower intracellular concentrations. Thus, spectroscopically
bioorthogonal Raman-active tags have been adopted which act as
markers for the small molecule of interest and improve detection
sensitivity. Spectroscopically bioorthogonal Raman tags share
many features in common with the bioorthogonal groups used
in click chemistry applications, since in both cases the groups
must be inert towards cellular decomposition (e.g. by water) and
reactivity (e.g. with cellular nucleophiles); the most widely studied
spectroscopically bioorthogonal group is the alkyne moiety.
These Raman tags may be inherent to the structure under
investigation (e.g. the alkyne functional groups present in
erlotinib and EdU, Fig. 7), or alternatively they may be incorpo-
rated through modification of the parent structure. In general,
they are much smaller than fluorescent tags and show greater
photostability than their fluorescent counterparts (i.e. the intensity
of the Raman signal does not decay with prolonged exposure).
Metabolic incorporation of the thymidine analogue EdU
into DNA, followed by CuAAC click reaction staining of the bio-
orthogonal alkyne of EdU with fluorescent azides, has emerged
as a powerful means of visualising DNA synthesis.55–57 This
bioorthogonal click chemistry approach to labelling is attrac-
tive because it is possible to chemically label species with high
specificity using a range of ligation techniques (Fig. 8A).58
However, incorporation of a bioorthogonal Raman-active tag
within a drug, or drug delivery vehicle, could potentially enable
direct visualisation by Raman microscopy (Fig. 8B), negating the
requirement for subsequent bioorthogonal chemical reactions.
Alkyne-tag Raman imaging (ATRI) was proposed in 2011 by
Yamakoshi et al. as a practical means to image cellular processes,
utilising a small alkyne tag to provide chemical contrast in the
spontaneous Raman image.46,59 Real-time visualisation of DNA
synthesis in living cells, without prior fixing or staining protocols,
Table 2 Raman-active probes
Entry Raman probe
Wavenumber
(cm1)
Application
Spontaneous Raman imaging SRS imaging
1 B2120 Uptake of deuteriated drug carriers. Ref. 47 Deuteriated choline metabolism. Ref. 48
2 B2110 Intracellular localisation of erlotinib. Ref. 49 Intracellular localisation of EdU. Ref. 50
3 B2120–2240 Intracellular localisation of FCCP. Ref. 21 Intracellular localisation of rhabduscin. Ref. 51
4 B688 Perfluorinated agrochemical uptake inplant leaves. Ref. 52
5 B1900–2050a Cellular localisation of Re and Mnbased therapeutics. Ref. 53 and 54
6 B2096
a The wavenumber will invariably change with coordination of the ligand to diﬀerent metal centres with diﬀerent electronic configurations and
diﬀerent coordination spheres, as indicated in the two referenced examples.
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has been achieved using both spontaneous Raman and SRS
imaging of the alkyne band of EdU.46,50,59 Hong et al. showed
that HeLa cells treated with EdU showed a significant SRS
signal (at 2120 cm1) due to the alkyne in the nucleus.50 This
spectroscopically bioorthogonal signal was abolished by treat-
ment with hydroxyurea (a DNA synthesis inhibitor), indicating
that it did indeed result from metabolic incorporation of EdU
during DNA synthesis. Min and co-workers showed that the
limit of detection of intracellular EdU using SRS was 200 mM.60
Tracking dividing cells every 5 minutes during mitosis neatly
demonstrated the acquisition speed, resolution and live cell
dynamics of SRS imaging (Fig. 9).60
Whilst the metabolic incorporation of EdU into DNA is the
most studied example of ATRI, other alkyne-tagged small
molecules which have been incorporated metabolically include:
(i) homopropargylglycine50 (Hpg, Fig. 7), a methionine analogue
with an SRS signal at 2120 cm1, which can be incorporated
in protein synthesis in methionine auxotrophic species;
(ii) 17-octadiynoic acid50 (ALK-16, Fig. 7), an alkyne-containing
palmitoyl acid analogue with an SRS signal at 2120 cm1, which
allows the distribution of proteins lipidated with this particular
fatty acid (the so-called palmitoylome) to be tracked in live
cells; (iii) 3-O-propargyl-D-glucose61 (3-OPG, Fig. 7), an alkyne
containing glucose analogue, which enabled monitoring of
glucose uptake and activity in living cells and tissues using the
SRS signal at 2129 cm1 and (iv) the monosaccharide precursor
peracetylated N-(4-pentynoyl)mannosamine (Ac4ManNAl, Fig. 7),
which is metabolised to the corresponding sialic acid derivative
and incorporated into sialyl-glycans imaged at 2120 cm1.50
El-Mashtoly et al. have imaged the distribution of the
epidermal growth factor receptor (EGFR) inhibitor, erlotinib
(Fig. 10); which is a frontline therapy used in the treatment of
non-small cell lung cancer.49 Erlotinib has a conjugated aryl
alkyne moiety, which gives rise to a comparatively intense Raman
signal. The group demonstrated that changes to the spontaneous
Raman cellular spectrum of erlotinib, as compared to free erlotinib,
indicated that intracellular metabolism gave the desmethyl deriva-
tive. However, the concentrations of erlotinib and its desmethyl
metabolite detected byHPLC and LC-MS analysis (of human plasma
from patients following the recommended 150 mg daily doses)
Fig. 7 Structures of molecules containing alkyne groups, which act as
bioorthogonal markers for spontaneous Raman and SRS imaging. Erlotinib
is a clinical drug which has an inherent alkyne bond, EdU is a thymidine
analogue modified with an alkyne bond, Hpg is an alkyne containing
methionine analogue, ALK-16 is a palmitic acid analogue modified with
an alkyne group, 3-OPG is a glucose analogue modified with a propargyl
group and Ac4ManNAI is an alkyne-containing glycan analogue.
Fig. 8 Strategies for intracellular visualisation of biomolecules. (A) Bioorthogonal
ligation strategy illustrated using a CuAAC click reaction. (B) Bioorthogonal
Raman-active tagging strategy. A small Raman reporter installed onto, or inherent
to, the biomolecule of choice is used as a marker to perform direct spontaneous
Raman or SRS imaging.
Fig. 9 Live SRS imaging of de novo synthesis of DNA. (A) Live HeLa cells
incubated with EdU alone (100 mM) alkyne on; and with hydroxyurea
(10 mM) control. (B) Time-lapse images of a dividing cell incubated with
EdU (100 mM). Scale bars: 10 mm. Adapted from ref. 60 with permission.
Copyright (2014) Nature Publishing group.
Fig. 10 Spontaneous Raman imaging of erlotinib. (A) Representative
spontaneous Raman spectrum of erlotinib showing clearly the strong
alkyne band at 2110 cm1. Spectrum acquired at 785 nm excitation.
(B) Spontaneous Raman imaging of SW480 cells treated with erlotinib
(B100 mM, 12 h) (i) spontaneous Raman image reconstructed from the
C–H stretching intensity; (ii) spontaneous Raman image constructed from
the CRC stretching intensity; (iii) overlay of panels (i) and (ii) showing
the drug is clustered at the EGFR protein at the cell membrane. Adapted
from ref. 49 with permission. Copyright (2014) Royal Society of Chemistry
publishing.
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are 3–5 mM and 0.3–0.7 mM respectively.62,63 At present, it is not
possible to detect such low concentrations using spontaneous
Raman spectroscopy, suggesting further improvements are
required before this method is clinically relevant.49
Aryl-conjugated alkynes have also been used in the spontaneous
Raman imaging of mitochondria in live cells using lipophilic
cationic phosphonium derivatives based on bisarylbutadiyne
(BADY).64 The use of the bisarylbutadiyne motif (imaged
at 2220 cm1) in these compounds generates mitochondrial
imaging agents with signals 27 times more intense than that
of EdU. Similar butadiyne motifs have been incorporated into
cholesterol65 and sphingomyelin.66
Other alternative markers for spectroscopically bioorthogonal
Raman imaging include azides, nitriles and inorganic metal–
carbonyl complexes. Perhaps surprisingly, although both the
alkyne and azide units which participate in the CuAAC click
reaction have diagnostic peaks which fall into the cellular silent
region of the Raman spectrum, and may therefore represent
smaller tags for Raman spectroscopy,46 the azide group has yet
to be used in this context. This is most probably due to the
reduced polarizability of the azide bond which gives rise to a
lower observed Raman scattering intensity.
Nitriles are also attractive markers for Raman microscopy
because of their widespread usage in medicinal chemistry as a
carbonyl bioisostere,67 with potential for visualisation of the
un-modified drug molecule. Crawford et al. demonstrated SRS
microscopy of rhabduscin (Fig. 11A), a tyrosine-derived amido-
glycosyl- and vinyl-isonitrile product in E. coli using the isonitrile
functional group as an intrinsic Raman tag.51 Genetically trans-
formed E. coli which heterologously expressed the rhabduscin
pathway, showed significant rhabduscin localisation in the cell
periphery (Fig. 11B), whilst E. coli lacking the rhabduscin gene
cluster showed minimal signal from the isonitrile functional
group probed at 2121 cm1 (Fig. 11B). Yamakoshi reported the
simultaneous imaging of the protonated and deprotonated
forms of carbonylcyanide p-trifluoromethoxy-phenylhydrazone
(FCCP) by spontaneous Raman microscopy, in which the nitrile
moiety serves as an intrinsic Raman tag (Fig. 11C).21
Nitrile tags have also been used to label lysine residues
within bovine serum albumin (BSA), using the NHS ester of
p-cyano-benzoic acid to install the nitrile tag.68 The modified
protein was shown to retain its wild-type function, demonstrating
the benefits of the small-sized Raman-active nitrile tag. Finally,
Kraﬀt has also demonstrated the subcellular distribution of
amygdalin (Fig. 11D), a nitrile containing glycoside, in thick
apricot seed sections by spontaneous Raman spectroscopy.69
Metal–carbonyl (M’ CRO) ligands have also been used in
spontaneous Raman microscopy studies to monitor the cellular
uptake of inorganic complexes. Policar et al. investigated
the cellular localisation of mestranol, an estrogen derivative
bearing a terminal alkyne unit, through its CuAAC click reaction
to a metal–carbonyl containing inorganic complex (Fig. 11D).53
The CRO ligands of the rhenium complex used in this study
displayed characteristic vibrational modes at 1915 cm1 and
2032 cm1. These Raman bands were used in confocal Raman
microscopy to determine the cellular localisation of the
conjugated mestranol in MDA-MB-231 breast cancer cells.
Similarly, Meister et al. used the CRO ligands of a manganese-
based therapeutic as a bioorthogonal Raman marker for direct
intracellular spontaneous Raman microscopy.54
3.2 Isotopologues as markers in Raman microscopy
The use of isotopologues has recently been demonstrated as an
alternative Raman tagging strategy. Isotopologues are chemical
compounds which are structurally identical but diﬀer only in
their isotopic composition. Deuterium (2H) and carbon-13 (13C)
have been shown to be useful isotopic substitutions for Raman
spectroscopy. The principle benefits of this strategy are that
isotopologues have almost identical size and electronic char-
acteristics to the parent compounds; but they may display
favourable Raman spectral characteristics, particularly as C–D
bands fall into the cellular silent region (B2100 cm1). Replacing
the hydrogen atoms in a molecule with deuterium, may even
improve metabolic stability, and the resultant deuteriated mole-
cules are typically safe to handle and dose to patients.70,71
The detection of deuteriated proteins in living eukaryotic
cells by spontaneous Raman spectroscopy was reported by van
Manen et al.72 Incubation of cells (Fig. 12A) with unlabelled
phenylalanine and deuteriated phenylalanine enabled quantifi-
cation of the incorporation of deuteriated amino acid by com-
parison of the labelled (959 cm1) and unlabelled (1001 cm1)
Raman bands. A better signal to noise ratio was achieved by
Fig. 11 Recent examples of biomolecules studied by SRS and sponta-
neous Raman imaging. (A) Rhabduscin. (B) SRS microscopy analysing the
spatial localisation of rhabduscin based on the vibrational resonance of
the isonitrile functional group at 2121 cm1. (i) Rhabduscin is localised at
the periphery of E. coli cells heterologously expressing the rhabduscin
pathway; (ii) the background signal is low in the cells lacking the rhabdus-
cin gene cluster. Scale bar 10 mm. Adapted from ref. 51 with permission
from the National Academy of Sciences. (C) FCCP (D) amygadalin
(E) mestranol and its conjugation to an inorganic coordination complex
via a CuAAC click reaction.
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quantifying the ring breathing phenylalanine peak at
B1000 cm1, rather than the C–D peaks at B2100 cm1. In
contrast, quantification of tyrosine and methionine incorpora-
tion was best achieved using their C–D signals at 2100–
2300 cm1. Culturing cells with 13C-labelled glucose or 15N-labelled
ammonium chloride (Fig. 12B) leads to metabolic incorpora-
tion of these heavy atoms in the growing cells. Shigeto et al.
noted that for S. pombe cells cultured in a 13C-glucose (Fig. 12B)
enriched medium, the subsequent incorporation of 13C could
be detected by monitoring the shift of the phenylalanine ring
breathing band from 1003 cm1 to 967 cm1.73 Shen et al. used
a similar shift when employing fully labelled 13C-phenylalanine
(Fig. 12B) to visualise protein degradation in living cells with
subcellular resolution by SRS microscopy.74
Single cell Raman spectroscopy (SCRS) can be used to char-
acterise heavy atom incorporation and provide information on
diﬀerent cell types, physiological states and phenotypes. Wang
et al. have recently shown that technical advances mean that SCRS
can even be used as a means of cell sorting.75 SRS microscopy
in tandem with metabolic incorporation of deuteriated amino-
acids has been used to visualise nascent proteins,76 enabling
SRS studies into protein synthesis and degradation in live cells,
brain tissue, zebrafish and live mice in vivo.76,77 These studies
have indicated fast protein turn-over in nucleoli, which is in
agreement with data obtained by fluorescence imaging using a
click labelling strategy.78
Labelling strategies using 13C-substitution have also been
applied successfully to study cell penetrating peptides,79 and
single-walled carbon nanotubes conjugated to therapeutic
agents,80 demonstrating the versatility of isotopic substitution
in Raman microscopy. Isotopic substitutions have recently been
used to extend alkyne tag chemistry to facilitate multiplexing
experiments. Chen et al. developed a three-colour vibrational
palette of alkyne tags based upon a 12C and 13C isotopic editing
strategy, enabled by an elegant alkyne cross metathesis protocol
(Fig. 13).81
Three alkyne isotopologues were prepared (the unlabelled
12CR12C, mono-labelled 13CR12C, and the bis-labelled
13CR13C alkynes); these exhibited diﬀerent stretching fre-
quencies in their Raman spectra as a consequence of the
diﬀerence in reduced mass, m, for the 12C and 13C isotopes.
With the isotopologues in hand, three colour chemical imaging
of DNA synthesis was reported.81
4. Biomedical applications of SRS
microscopy
Raman microscopy allows the intracellular concentrations of
biomolecules to be imaged. This has sparked research into
Raman imaging across a range of biomedical applications,
from the study of drug uptake and distribution, to investiga-
tions into cellular metabolism and storage, and mechanistic
studies on drug delivery agents and pathways. Here, we outline
case studies where spontaneous Raman microscopy and SRS
microscopy have advanced current understanding in each of
these areas. Clearly, the benefits provided by Raman imaging
are not restricted to biomedical applications, and thus the final
section highlights recent advances in the Raman imaging of
agrochemical uptake.
4.1 Case study 1: cellular drug distribution
Growing evidence suggests that measurement of the physio-
chemical properties of a drug molecule within early stage drug
discovery and development is crucial to reducing the current
high attrition rates of new chemical entities on entering late
stage development programmes,82 and an improved understanding
Fig. 12 Incorporation of Raman-active isotopologues into proteins and
biomolecules. (A) Metabolic incorporation of labelled amino acids in
auxotrophic cell lines. (B) Raman-active metabolic precursors: deuteriated
phenylalanine, 15N-labelled ammonium chloride, 13C-labelled glucose,
13C-labelled phenylalanine.
Fig. 13 Development of a three colour palette of alkyne tags. (A) Struc-
tures of unlabelled, mono, and bis 13C-labelled 5-ethynyl-20-deoxyuridine
(EdU). (B) Spontaneous Raman spectra of HeLa cells incubated with the
three isotopically edited EdU’s (0.1 mM, 15 h). Spectra were acquired from
the nuclear region of fixed cells following incubation with either 1, 2 or 3.
The spectra were normalised at the alkyne peak, and are displayed from
2000–2170 cm1. (C) Live cell SRS imaging of DNA synthesis in HeLa cells
incubated with isotopically edited EdUs. For each sample incubated
with either 1, 2, or 3. Images are acquired in 5 different Raman channels:
1655 cm1 (amide I band), 2000 cm1 (off-resonant), 2048 cm1
(on-resonant with 3), 2077 cm1 (on-resonant with 2), and 2125 cm1
(on-resonant with 1) in sequential mode. Images are acquired in 512 512 pixels
with a pixel dwell time of 40 ms. Image adapted from ref. 81 with permission.
Copyright (2014) American Chemical Society.
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of the cellular concentration and localisation of a new drug
molecule in relevant cells and tissues, represents a key challenge
in early stages of drug discovery campaigns.83 Specifically, poor
biopharmaceutical properties associated with drug uptake,
retention, metabolism and solubility are directly related to poor
clinical success.84,85 The application of imaging modalities to
drug discovery programmes has the potential to accelerate
preclinical lead optimisation cycles and enhance the in vitro to
in vivo translation of drug candidates.11,16
Several examples of studies which use Raman imaging to
probe intracellular drug distribution have been published very
recently. Firstly, Baik et al. used spontaneous Raman spectro-
scopy to monitor the intracellular accumulation of the anti-
biotic clofazimine (Fig. 14).22 This study also confirmed the
amorphous nature of the drug in the discrete clofazimine
inclusions formed in the cytoplasm by comparison of their
Raman spectra with amorphous and crystalline forms of the
solid drug. Carey et al. monitored the penetration of two
antibiotics, clavulanic acid and tazobactam, into bacterial cells
based upon the Raman activity of characteristic features from
clavulanic acid (1695 cm1 CQC band) and tazobactam
(626 cm1 C–S stretch) (Fig. 14).23 Changes in the spontaneous
Raman spectrum of these drugmolecules during a drug treatment
cycle were monitored, and the formation of the acyl–enzyme
complex between the inhibitors and the b-lactamase enzyme
could also be detected. However, the protocol employed on
the drug-treated cells for visualisation by spontaneous Raman
required lengthy pelleting and freeze-drying procedures, prohi-
biting direct live-cell imaging and drug localisation studies.
Erlotinib is a clinically relevant drug, which is used in the
treatment of non-small cell lung cancers, and has been recently
studied by confocal Raman microscopy, using the inherent alkyne
bond as a marker for intracellular visualisation (see Fig. 10).49
More recently, advances in hsSRS imaging have enabled the
intracellular visualisation and localisation of other un-modified
drugs which do not contain a bioorthogonal functional group.
Fu et al. elegantly described the first direct observation and
quantification of tyrosine kinase inhibitors (TKIs) in living
chronic myelogenous leukaemia (CML) cells.86 Prior acquisi-
tion of the spontaneous Raman spectrum for each of the drugs
enabled identification of their major Raman bands. Cellular
imaging of these drugs by hsSRS used peaks that were inherent
to the structure of the drug compounds and were not necessarily
located within the ‘cellular silent region’; potentially widening
the scope of this approach over spectroscopically bioorthogonal
tagging strategies. Fig. 15 shows the SRS images of BaF3/BCR-
ABL1 cells treated with imatinib, nilotinib and DMSO (control)
obtained in this study. Lysosomal localisation of these drugs
was corroborated by co-localisation with the fluorescent stain
LysoTracker Red, using two-photon excitation. Since SRS signals
show a linear dependence on concentration, intracellular drug
concentrations can be determined based on calibrations against
standard solutions of each of the drugs. Cells were treated with
20 mM imatinib or 20 mM nilotinib, and imaged by hsSRS. Both
drugs were enriched by more than 1000-fold in lysosomes; hence
reducing the availability of cytosolic drug, and ultimately redu-
cing drug eﬃcacy. Analysis of the hsSRS images also showed the
cytosolic concentrations of these drugs to be below the current
detection limit (1–2 mM). This study shows that hsSRS imaging
offers unprecedented capability in label-free drug visualisation,
and is applicable to pharmacokinetic studies.
Liposomal drug carriers can also be imaged via Raman
microscopy. Chernenko et al. incubated MCF-7 cells with a
deuteriated liposomal drug carrier (DSPC-d70), to determine
the distribution patterns of these drug delivery systems.47,87
When images were acquired using the C–D stretching region
between 2000–2310 cm1, a cytoplasmic distribution of DSPC-
d70 and its accumulation in the cell periphery were observed.
However, the spontaneous Raman microscope used in these
studies required lengthy scanning times (approximately 1 h
required to image one entire cell), thus illustrating the clear need
for the video-rate image acquisition achieved with SRS micro-
scopy. Other drug delivery mechanisms analysed by spontaneous
Raman spectroscopy include targeted drug delivery via gold88,89
and graphene oxide silica nanoparticles,90 biodegradable poly-
meric nano-carrier systems91 and nanocolloids.92
4.2 Case study 2: cellular metabolism and lipid storage
Maintaining physiological homeostasis requires strict regula-
tion of a multitude of cellular processes. The control of cellular
and systemic lipid levels is of particular significance in main-
taining a healthy phenotype, with excessive cholesterol levels
resulting in toxicity, and dysregulation of sterol metabolism
Fig. 14 Structures of drugs which have been imaged by spontaneous Raman
spectroscopy, and SRS microscopy, highlighting the key bonds and Raman
stretching frequencies which have enabled their intracellular quantitation. Note:
for clofazimine a range of peaks were used in the region 1100–1600 cm1.
Fig. 15 Maximum-intensity projection of 3D SRS images at 1305 cm1 of
BaF3/BCR-ABL1 cells incubated with (A) imatinib (20 mM, 4 h), (B) nilotinib
(20 mM, 4 h), and (C) DMSO only. Scale bar 5 mM. Adapted from ref. 86 with
permission. Copyright (2014) Nature Publishing Group.
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being a hallmark of diabetes and atherosclerosis.93 Imbalances
in lipid metabolism have been implicated in several diseases
(including cancer, atherosclerosis, and diabetes), highlighting the
importance of understanding lipid biochemistry in disease.94,95
Thus mapping lipid oxidation, the degree of lipid unsaturation
and cholesterol storage in vivo may prove fruitful in developing
novel approaches to tackling a range of diseases. To this end,
several recent studies have demonstrated Raman imaging of lipid
storage and metabolism.
C. elegans can provide useful predictive data for studying drug-
target interactions and for target validation.96 hsSRS was used by
Wang et al. for in situ identification and quantification of distinct
lipid compartments in living C. elegans (Fig. 16).97 Imaging in the
region 1620–1800 cm1 [which covers (i) sterol CQC (1669 cm1),
(ii) triglyceride CQC (1655 cm1) and CQO (1745 cm1), and (iii)
protein amide I CQO (1650 cm1) bands] enabled the generation
of quantitative chemical maps based upon the intensity ratio of the
Raman bands, and has allowed the analysis of lipid unsaturation,
lipid oxidation and cholesterol storage, through multivariate curve
analysis (MCR). These data showed that lysosome related orga-
nelles (LROs) are cholesterol storage sites in C. elegans. Similar
approaches have been used to image cholesterol storage in athero-
sclerotic arterial tissues.98
hsSRS has also been used by Fu and co-workers for the
quantification of two major lipidic components in cells and
tissues, cholesteryl ester and triacylglycerol.99 Their approach
highlighted previously unknown changes in lipid composition
associated with obesity and related diseases.99 These direct
measurements of the impact of lipid storage and biochemistry,
further demonstrate the applicability of SRS imaging in vivo as
a tool for the drug discovery process.
4.3 Case study 3: dermal drug delivery
Diseases of the skin are typically alleviated by application of
topical drug formulations. Dermal formulations can oﬀer
advantages over oral drug delivery because direct targeting of
the local aﬀected area is easily achieved through dermal applica-
tion, compared to systemic exposure through oral delivery.
However, the impermeable nature of skin hinders the wide-
spread uptake of chemical species, with only small lipophilic
compounds eﬀectively delivered via the transdermal route.100
Recent reports indicate that despite significant research eﬀorts
focussed upon transdermal drug discovery, only modest achieve-
ments have been realised.101
Excised specimens of animal and human skin have been used
as models to test drug permeation. However, practical problems
may arise with a lack of available tissue and the quality of excised
tissue. Furthermore, cutaneous bioavailability studies are often
performed using adhesive tape stripping, whereby the outermost
layer of the skin, the stratum corneum (SC), is sequentially
revealed, and the concentration of drug present is determined
with each strip, to produce a concentration profile across the tissue
depth.102 This approach is hampered by issues relating to the
timing of the tape strippings, the number of removals which can
make the process onerous and unsuitable for high throughput
screening, and whether the strips reveal the same amount of SC
each time. Therefore, alternative approaches for monitoring the
bioavailability of drugs and their excipients would be beneficial to
drug discovery programmes focussed upon dermal delivery.
Raman spectroscopy is emerging as an alternative approach
to understanding topical drug delivery;102,103 and SRS may
potentially enable the analysis of drug toxicity on live skin,
which is not feasible using tape stripping on excised specimens.
SRS microscopy has been used to probe epidermal architecture
by collecting images at frequencies corresponding to protein
(2950 cm1), lipid (2850 cm1) and water (3340 cm1). Depth
profiles were collected to a range of 28 mm, to provide further
insight into the chemical nature of micro-anatomical features of
skin.103 A deuteriated oleic acid, was shown to distribute to lipid
rich regions within the skin after topical application.103 This
allowed the diﬀerentiation of drug localisation, which could not
be determined by the tape stripping methods.
Drug delivery to the skin has also been demonstrated
through monitoring the prominent Raman bands of DMSO
and retinoic acid, and mapping their cell penetration through
depth profiling SRS microscopy.27 Lateral profiling of topically
applied retinoic acid (1570 cm1) and DMSO (670 cm1), demon-
strated that the hydrophobic retinoic acid penetrates through the
lipid rich regions, whilst the hydrophilic DSMO avoids lipid-rich
skin structures such as adipocytes in the subcutaneous fat
layers.27 SRS microscopy has also demonstrated that the alkyne-
containing anti-fungal dermal drug, terbinafine hydrochloride
(TH), penetrates through skin in the lipid phase (Fig. 17).60
Finally, the uptake of a range of pharmaceutically relevant
solvents (water, propylene glycol and DMSO) in human nail
samples has also been imaged by SRS using their deuteriated
isotopologues to provide label-free chemical contrast.104
Optimisation of topical drug delivery for the treatment of
several dermatological diseases was explored by Xie and Guy,
who demonstrated the capability of SRS to provide kinetic and
mechanistic insights into the transdermal drug delivery process.105
Fig. 16 Compositional analysis of intracellular compartments in whole
C. elegans worms by hsSRS imaging, k-means clustering, and MCR analysis.
(A and B) MCR-retrieved concentration maps of neutral fat droplets,
lysosome-related organelles (LROs), oxidised lipids, and protein in the body
of whole wild type worms (A) and daf-2 mutants (B). Scale bar: 50 mm.
(C) Zoom-in of intestine cells indicated in (B). (D–G) MCR-reconstructed
concentration images of LROs, fat droplets, oxidised lipids, and protein,
respectively. Adapted from ref. 97 with permission. Copyright (2014) Wiley-
VCH Verlag GmbH & Co kGaA, Weinheim.
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Notably, SRS imaging provided evidence of drug precipitation
from the applied formulation, post application onto the skin.
Whilst following the penetration of deuteriated ibuprofen in
un-deuteriated propylene glycol, images of the C–D stretching
frequency (2120 cm1) of the ibuprofen-d3 confirmed the
formation of ibuprofen crystals at the skin surface. Belsey
et al. also demonstrated time course imaging of porcine skin
dosed with ketoprofen in deuteriated propylene glycol by SRS
imaging.106
In summary, SRS microscopy has advanced current under-
standing within dermato-pharmacokinetics, highlighting pre-
viously unknown aspects of drug delivery to the skin. Novel
features of drug delivery have been identified including the
diﬀerent rates of drug penetration via hair follicles and through
intracellular diﬀusion, and interesting features of formulation
application. Monitoring changes in the morphology of skin
cells via SRS imaging following drug application, may enable
toxicity studies to be performed on topically applied drugs,
significantly improving on available methodologies.
4.4 Case study 4: agrochemical uptake
The development of agrochemical agents including herbicides,
fungicides and insecticides relies heavily on understanding the
environmental impact the agrochemicals and any potential
metabolites will have. Furthermore, prior to achieving regula-
tory approval, studies to demonstrate that the compounds do
not persist in the environment considerably beyond their
period of intended use, and that they are eﬃcacious against
their intended target are required.107,108 Such information is
necessary because typically agrochemicals are applied over
large areas in agricultural and urban environments.108 Impor-
tantly, understanding the uptake, translocation and metabo-
lism of herbicides into foliar tissue and roots directly
influences the activity, persistence and crop selectivity in the
field. Traditional methods of measuring uptake and movement
of agrochemicals include HPLC, autoradiography and liquid
scintillation techniques.109 Recently, Clench et al. have demon-
strated a mass spectrometry based imaging approach to follow-
ing agrochemical translocation in sunflower plants.110 Such
techniques however, are limited by factors such as their
destructive nature (making it diﬃcult to obtain information
from living plant leaves) and the time and expense of radio-
chemical synthesis (prohibiting uptake studies in the early
stage agrochemical development).
Conventional Raman microscopy has been utilised to study
the chemical composition of various features of plant leaves.111
More recently, Mansfield et al. demonstrated the applicability
of SRS imaging for the analysis of plant cell wall components,
epicuticular waxes and the deposition of agrochemical formu-
lations directly onto leaf surfaces.112 Interestingly, the group
were able to use the nitrile functional group present within two
agrochemicals, chlorothalonil and azoxystrobin to perform
spectroscopically bioorthogonal SRS microscopy (at 2234 and
2225 cm1 respectively), which revealed crystalline deposits on
the leaf surfaces (Fig. 18), whilst the CH3 vibrations at 2930 cm
1
provided structural information on the plant cell walls.
Finally, SRS microscopy has been extended to the imaging of
perfluorinated agrochemicals, which was achieved via excita-
tion of the C–F bonds at 687.5 cm1.52 This use of a vibrational
frequency which lies outside the cell silent region provides an
important expansion to the current ‘toolbox’ approach to
chemical labelling; with a functional group which is both
medicinally relevant, and offers significant benefits for SRS
detection. These early studies represent novel approaches
to understanding agrochemical uptake in plants in a rapid,
non-destructive manner, which could therefore present new
opportunities in early stage agrochemical development.
Fig. 17 SRS imaging of mouse ear skin with topically applied terbinafine
hydrochloride (TH). (A) Terbinafine hydrochloride. (B) SRS imaging at the
viable epidermis layer (z = 20 mm), (C) SRS imaging at the sebaceous gland
layer (z = 40 mm) of mouse ear skin. In both (B and C), composite images
show both protein (1655 cm1) and lipid (2845 cm1) distributions, and the
alkyne images indicate that the TH penetrates via the lipidic phase. Scale
bars, 20 mm. Adapted from ref. 60 with permission. Copyright (2014)
Nature Publishing Group.
Fig. 18 Application of azoxystrobin to maize leaves. (A) Azoxystrobin
applied to a maize leaf (red = 2225 cm1 from the CRN bond, green =
2930 cm1 from the CH3 vibrations) to show crystalline deposits of the
chemical on the leaf surface, which appear yellow/orange due to contrast
from the CH bonds (green) and CN bonds (red) which have been
combined. (B) Chemical structure of azoxystrobin. Adapted from ref. 112
with permission. Copyright (2013) American Chemical Society.
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5. Conclusions
Live cell Raman imaging when coupled with bioorthogonal
labelling strategies is emerging as a promising imaging
modality applicable to drug discovery and medicine. The direct
visualization of bioorthogonal Raman reporters avoids the need
for further fixing, and click-labelling strategies, which thereby
improves sample throughput and accommodates live-cell imaging.
The low sensitivity of the Raman scattering process still remains a
significant limitation of the approach, where inmany cases, typical
detection limits are above physiologically relevant drug concentra-
tions. Advances in Raman tag design and technical instrument
improvements are expected to make further gains in detection
sensitivity. The use of advanced Raman scattering techniques,
namely SRS, and the incorporation of hyperspectral and multi-
plexing approaches will also likely transcend detection and
imaging speed limits. However, these early studies indicate
the exciting potential of Raman microscopies to shed light on
our understanding of how small molecules interact with cells
and tissues, providing significant benefits to early-stage drug
discovery projects.
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